S. ++%, 5)()&%-$+'&)&)6A)<"<A)

. '. %a&%, Q$(&% '51, 6%A&&)!B&$A&&)&-)A&&)$&//)A&$&+& 1&5&) ,$2$

&. =%4+&&, %C)($%/6-&%)6-&)%CP-1&$+4$A)%QQ, pp.5-6

'. &%c4%, 66-)4)6)-&)

&. !. >^p-'e and !. Qq-'%-!-%, &)4)6)-&)A+&)6), p.66

%. %+, %4)+51'-$)*%A-4

%. and %. %a, A& )()&4+&(6)*%%C'&)&66&!$&&%

/. %%&, 5+-)*%-5()%+& -$&$1

A. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff et al., Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent., Proceedings of the National Academy of Sciences, vol.77, issue.7, pp.3957-61, 1980.
DOI : 10.1073/pnas.77.7.3957

D. Bilheimer, S. Grundy, M. Brown, and J. Goldstein, Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes., Proceedings of the National Academy of Sciences, vol.80, issue.13, pp.4124-4132, 1983.
DOI : 10.1073/pnas.80.13.4124

D. Bilheimer, S. Grundy, M. Brown, and J. Goldstein, Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes., Proceedings of the National Academy of Sciences, vol.80, issue.13, pp.1-9, 1983.
DOI : 10.1073/pnas.80.13.4124

D. Blankenhorn, S. Azen, D. Kramsch, W. Mack, L. Cashin-hemphill et al., Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS), Annals of Internal Medicine, vol.119, issue.10, pp.969-76, 1993.
DOI : 10.7326/0003-4819-119-10-199311150-00002

R. Bradford, C. Shear, A. Chremos, C. Dujovne, M. Downton et al., Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia, Archives of Internal Medicine, vol.151, issue.1, pp.43-52, 1991.
DOI : 10.1001/archinte.151.1.43

B. Brown, J. Albers, L. Fisher, S. Schaefer, J. Lin et al., Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B, New England Journal of Medicine, vol.323, issue.19, pp.1289-98, 1990.
DOI : 10.1056/NEJM199011083231901

L. Cashin-hemphill, D. Kramsch, P. Azen, D. Demets, L. Deboer et al., The monitored artherosclerosis regression study (MARS), On line J of Curr Clin Trials, pp.1059-2725, 1992.

D. Delong, A Comparison of Methods for the Estimation of Plasma Low- and Very Low-Density Lipoprotein Cholesterol, JAMA, vol.256, issue.17, pp.2372-77, 1986.
DOI : 10.1001/jama.1986.03380170088024

C. East, P. Alivizatos, S. Grundy, P. Jones, and J. Farmer, Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation, N Engl J Med, vol.318, issue.1, pp.47-55, 1988.

C. East, S. Grundy, and D. Bilheimer, Preliminary report: Treatment of type 3 hyperlipoproteinemia with mevinolin, Metabolism, vol.35, issue.2, pp.97-105, 1986.
DOI : 10.1016/0026-0495(86)90106-X

D. Fredrickson, R. Levy, and R. Lees, Fat Transport in Lipoproteins ??? An Integrated Approach to Mechanisms and Disorders, New England Journal of Medicine, vol.276, issue.3, pp.148-56, 1967.
DOI : 10.1056/NEJM196701192760305

C. Furberg, H. Adams, . Jr, W. Applegate, R. Byington et al., Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group, Circulation, vol.90, issue.4, pp.1679-87, 1994.
DOI : 10.1161/01.CIR.90.4.1679

A. Garg and S. Grundy, Lovastatin for Lowering Cholesterol Levels in Non-Insulin-Dependent Diabetes Mellitus, New England Journal of Medicine, vol.318, issue.2, pp.81-87, 1988.
DOI : 10.1056/NEJM198801143180204

J. Germershausen, V. Hunt, R. Bostedor, P. Bailey, J. Karkas et al., Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo, Biochemical and Biophysical Research Communications, vol.158, issue.3, pp.667-75, 1989.
DOI : 10.1016/0006-291X(89)92773-3

A. Ghidini, Congenital abnormalities (VATER) in baby born to mother using lovastatin, The Lancet, vol.339, issue.8806, pp.1416-1423, 1992.
DOI : 10.1016/0140-6736(92)91237-3

G. Ghirlanda, A. Oradei, A. Manto, S. Lippa, L. Uccioli et al., Evidence of Plasma CoQ10-Lowering Effect by HMG-CoA Reductase Inhibitors: A Double-Blind, Placebo-Controlled Study, The Journal of Clinical Pharmacology, vol.2, issue.3, pp.226-235, 1993.
DOI : 10.1002/j.1552-4604.1993.tb03948.x

S. Grundy, Dietary and drug regulation of cholesterol metabolism in man, Lipid Pharmacol, vol.2, p.127, 1976.

S. Grundy and D. Bilheimer, Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance., Proceedings of the National Academy of Sciences, vol.81, issue.8, pp.2538-2580, 1984.
DOI : 10.1073/pnas.81.8.2538

S. Grundy and G. Vega, Effects of mevinolin on plasma lipoprotein (LP) metabolism in moderate hypercholesterolemia, Circulation, vol.70, issue.4, p.268, 1984.

S. Grundy and G. Vega, Influence of mevinolin on metabolism of low-density lipoproteins in primary moderate hypercholesterolemia, J Lipid Res, vol.26, issue.12, pp.1464-75, 1985.

S. Grundy, G. Vega, and D. Bilheimer, Influence of Combined Therapy with Mevinolin and Interruption of Bile-Acid Reabsorption on Low Density Lipoproteins in Heterozygous Familial Hypercholesterolemia, Annals of Internal Medicine, vol.103, issue.3, pp.339-382, 1985.
DOI : 10.7326/0003-4819-103-3-339

J. Hoeg, M. Maher, K. Bailey, and H. Brewer, The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia, Atherosclerosis, vol.60, issue.3, pp.209-223, 1986.
DOI : 10.1016/0021-9150(86)90167-X

J. Hoeg, M. Maher, K. Bailey, and H. Brewer, Comparison of six pharmacologic regimens for hypercholesterolemia, The American Journal of Cardiology, vol.59, issue.8, pp.812-817, 1987.
DOI : 10.1016/0002-9149(87)91097-6

J. Hoeg, M. Maher, L. Zech, K. Bailey, R. Gregg et al., Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia, The American Journal of Cardiology, vol.57, issue.11, pp.933-942, 1986.
DOI : 10.1016/0002-9149(86)90733-2

D. Illingworth, How effective is drug therapy in heterozygous familial hypercholesterolemia?, The American Journal of Cardiology, vol.72, issue.10, pp.54-58, 1993.
DOI : 10.1016/0002-9149(93)90011-Z

D. Illingworth and W. Connor, Hypercholesterolemia Persisting After Distal Ileal Bypass: Response to Mevinolin, Annals of Internal Medicine, vol.100, issue.6, pp.850-851, 1984.
DOI : 10.7326/0003-4819-100-6-850

D. Illingworth and D. Corbin, The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia., Proceedings of the National Academy of Sciences, vol.82, issue.18, pp.6291-6295, 1985.
DOI : 10.1073/pnas.82.18.6291

D. Illingworth and G. Sexton, Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia., Journal of Clinical Investigation, vol.74, issue.6, pp.1972-1980, 1984.
DOI : 10.1172/JCI111618

D. Illingworth, Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia, Clinical Pharmacology and Therapeutics, vol.40, issue.3, pp.338-381, 1986.
DOI : 10.1038/clpt.1986.185

D. Illingworth, Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia, Annals of Internal Medicine, vol.101, issue.5, pp.598-604, 1984.
DOI : 10.7326/0003-4819-101-5-598

D. Illingworth, A. Pappu, and S. Bacon, Metabolic and clinical effects of mevinolin in familial hypercholesterolemia, Atherosclerosis, vol.VII, pp.611-615, 1986.

J. Krukemyer and R. Talbert, Lovastatin: A New Cholesterol-Lowering Agent, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol.76, issue.6, pp.198-210, 1987.
DOI : 10.1002/j.1875-9114.1987.tb03524.x

H. Mabuchi, T. Haba, R. Tatami, S. Miyamoto, Y. Sakai et al., Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia, New England Journal of Medicine, vol.305, issue.9, pp.478-82, 1981.
DOI : 10.1056/NEJM198108273050902

M. Malloy, J. Kane, S. Kunitake, and P. Tun, Complementarity of Colestipol, Niacin, and Lovastatin in Treatment of Severe Familial Hypercholesterolemia, Annals of Internal Medicine, vol.107, issue.5, pp.616-639, 1987.
DOI : 10.7326/0003-4819-107-5-616

D. Norman, D. Illingworth, J. Munson, and J. Hosenpud, Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin, N Engl J Med, vol.318, issue.1, pp.46-53, 1988.

S. Quérin, R. Lambert, J. Cusson, S. Grégoire, S. Vickers et al., Single-dose pharmacokinetics of 14 C-lovastatin in chronic renal failure, Clin Pharmacol Ther, pp.437-478, 1991.

A. Scanu, Lipoprotein(a) as a cardiovascular risk factor, Trends in Cardiovascular Medicine, vol.1, issue.7, pp.294-303, 1991.
DOI : 10.1016/1050-1738(91)90046-H

G. Smith, F. Song, and T. Sheldon, Cholesterol lowering and mortality: the importance of considering initial level of risk., BMJ, vol.306, issue.6889, pp.1367-71, 1993.
DOI : 10.1136/bmj.306.6889.1367

E. Stein, Treatment of familial hypercholesterolemia with drugs in children, Arteriosclerosis, vol.9, issue.1, pp.145-51, 1989.

G. Thompson, J. Ford, M. Jenkinson, and I. Trayner, Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolemia, Q J Med, vol.60, issue.232, pp.803-814, 1986.

J. Tobert, G. Bell, J. Birtwell, I. James, W. Kukovetz et al., Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers., Journal of Clinical Investigation, vol.69, issue.4, pp.913-922, 1982.
DOI : 10.1172/JCI110530

J. Tobert, Reply to two letters addressed to the Editor in The New England Journal of Medicine, N Engl J Med, vol.318, issue.1, p.48, 1988.

J. Tobert, G. Hitzenberger, W. Kukovetz, I. Holmes, and K. Jones, Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme a reductase, Atherosclerosis, vol.41, issue.1, pp.61-66, 1982.
DOI : 10.1016/0021-9150(82)90070-3

M. Traber and H. Kayden, Inhibition of cholesterol synthesis by mevinolin stimulates low density lipoprotein receptor activity in human monocyte-derived macrophages, Atherosclerosis, vol.52, issue.1, pp.1-11, 1984.
DOI : 10.1016/0021-9150(84)90152-7